Evidence for the transmission of parvovirus B19 in patients with bleeding disorders treated with plasma-derived factor concentrates in the era of nucleic acid test screening

J. Michael Soucie, Christine De Staercke, Paul E. Monahan, Michael Recht, Meera B. Chitlur, Ralph Gruppo, W. Craig Hooper, Craig Kessler, Roshni Kulkarni, Marilyn J. Manco-Johnson, Jerry Powell, Meredith Pyle, Brenda Riske, Hernan Sabio, Sean Trimble

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

BACKGROUND: Parvovirus B19 (B19V) is a small, nonenveloped virus that typically causes a benign flu-like illness that occurs most frequently in childhood. The virus is resistant to current viral inactivation steps used in the manufacture of antihemophilic factor concentrates and B19V transmission through these products has been documented. Since 2000, B19V nucleic acid test (NAT) screening of plasma pools has been implemented to further decrease the viral burden in these products, but no study has examined populations using these products to assess the impact of the screening on B19V transmission. STUDY DESIGN AND METHODS: Blood specimens obtained from participants of a surveillance system established in federally supported specialized bleeding disorders clinics were used in a B19V seroprevalence study. RESULTS: A total of 1643 specimens from 1043 participants age 2 to 7 years born after B19V NAT screening was implemented were tested. Age-specific prevalence rates were generally higher for subjects exposed to either plasma-derived products alone or in combination with other products compared to subjects with no exposure to antihemophilic products. Overall, compared to participants unexposed to blood or blood products, those exposed to plasma-derived products alone were 1.7 times more likely to have antibodies to B19V (p = 0.002). CONCLUSION: These results are consistent with continued B19V transmission through plasma-derived factor concentrates. Effective viral inactivation and detection processes are needed to protect users of these products from infection with B19V or other new or emerging viruses.

Original languageEnglish (US)
Pages (from-to)1217-1225
Number of pages9
JournalTransfusion
Volume53
Issue number6
DOIs
StatePublished - Jun 2013

Fingerprint

Parvovirus
Nucleic Acids
Hemorrhage
Virus Inactivation
Viruses
Seroepidemiologic Studies
Viral Load
Antibodies
Infection
Population

ASJC Scopus subject areas

  • Hematology
  • Immunology
  • Immunology and Allergy

Cite this

Evidence for the transmission of parvovirus B19 in patients with bleeding disorders treated with plasma-derived factor concentrates in the era of nucleic acid test screening. / Soucie, J. Michael; De Staercke, Christine; Monahan, Paul E.; Recht, Michael; Chitlur, Meera B.; Gruppo, Ralph; Hooper, W. Craig; Kessler, Craig; Kulkarni, Roshni; Manco-Johnson, Marilyn J.; Powell, Jerry; Pyle, Meredith; Riske, Brenda; Sabio, Hernan; Trimble, Sean.

In: Transfusion, Vol. 53, No. 6, 06.2013, p. 1217-1225.

Research output: Contribution to journalArticle

Soucie, JM, De Staercke, C, Monahan, PE, Recht, M, Chitlur, MB, Gruppo, R, Hooper, WC, Kessler, C, Kulkarni, R, Manco-Johnson, MJ, Powell, J, Pyle, M, Riske, B, Sabio, H & Trimble, S 2013, 'Evidence for the transmission of parvovirus B19 in patients with bleeding disorders treated with plasma-derived factor concentrates in the era of nucleic acid test screening', Transfusion, vol. 53, no. 6, pp. 1217-1225. https://doi.org/10.1111/j.1537-2995.2012.03907.x
Soucie, J. Michael ; De Staercke, Christine ; Monahan, Paul E. ; Recht, Michael ; Chitlur, Meera B. ; Gruppo, Ralph ; Hooper, W. Craig ; Kessler, Craig ; Kulkarni, Roshni ; Manco-Johnson, Marilyn J. ; Powell, Jerry ; Pyle, Meredith ; Riske, Brenda ; Sabio, Hernan ; Trimble, Sean. / Evidence for the transmission of parvovirus B19 in patients with bleeding disorders treated with plasma-derived factor concentrates in the era of nucleic acid test screening. In: Transfusion. 2013 ; Vol. 53, No. 6. pp. 1217-1225.
@article{8f92d0e5768d4117bff2b4650b515e17,
title = "Evidence for the transmission of parvovirus B19 in patients with bleeding disorders treated with plasma-derived factor concentrates in the era of nucleic acid test screening",
abstract = "BACKGROUND: Parvovirus B19 (B19V) is a small, nonenveloped virus that typically causes a benign flu-like illness that occurs most frequently in childhood. The virus is resistant to current viral inactivation steps used in the manufacture of antihemophilic factor concentrates and B19V transmission through these products has been documented. Since 2000, B19V nucleic acid test (NAT) screening of plasma pools has been implemented to further decrease the viral burden in these products, but no study has examined populations using these products to assess the impact of the screening on B19V transmission. STUDY DESIGN AND METHODS: Blood specimens obtained from participants of a surveillance system established in federally supported specialized bleeding disorders clinics were used in a B19V seroprevalence study. RESULTS: A total of 1643 specimens from 1043 participants age 2 to 7 years born after B19V NAT screening was implemented were tested. Age-specific prevalence rates were generally higher for subjects exposed to either plasma-derived products alone or in combination with other products compared to subjects with no exposure to antihemophilic products. Overall, compared to participants unexposed to blood or blood products, those exposed to plasma-derived products alone were 1.7 times more likely to have antibodies to B19V (p = 0.002). CONCLUSION: These results are consistent with continued B19V transmission through plasma-derived factor concentrates. Effective viral inactivation and detection processes are needed to protect users of these products from infection with B19V or other new or emerging viruses.",
author = "Soucie, {J. Michael} and {De Staercke}, Christine and Monahan, {Paul E.} and Michael Recht and Chitlur, {Meera B.} and Ralph Gruppo and Hooper, {W. Craig} and Craig Kessler and Roshni Kulkarni and Manco-Johnson, {Marilyn J.} and Jerry Powell and Meredith Pyle and Brenda Riske and Hernan Sabio and Sean Trimble",
year = "2013",
month = "6",
doi = "10.1111/j.1537-2995.2012.03907.x",
language = "English (US)",
volume = "53",
pages = "1217--1225",
journal = "Transfusion",
issn = "0041-1132",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Evidence for the transmission of parvovirus B19 in patients with bleeding disorders treated with plasma-derived factor concentrates in the era of nucleic acid test screening

AU - Soucie, J. Michael

AU - De Staercke, Christine

AU - Monahan, Paul E.

AU - Recht, Michael

AU - Chitlur, Meera B.

AU - Gruppo, Ralph

AU - Hooper, W. Craig

AU - Kessler, Craig

AU - Kulkarni, Roshni

AU - Manco-Johnson, Marilyn J.

AU - Powell, Jerry

AU - Pyle, Meredith

AU - Riske, Brenda

AU - Sabio, Hernan

AU - Trimble, Sean

PY - 2013/6

Y1 - 2013/6

N2 - BACKGROUND: Parvovirus B19 (B19V) is a small, nonenveloped virus that typically causes a benign flu-like illness that occurs most frequently in childhood. The virus is resistant to current viral inactivation steps used in the manufacture of antihemophilic factor concentrates and B19V transmission through these products has been documented. Since 2000, B19V nucleic acid test (NAT) screening of plasma pools has been implemented to further decrease the viral burden in these products, but no study has examined populations using these products to assess the impact of the screening on B19V transmission. STUDY DESIGN AND METHODS: Blood specimens obtained from participants of a surveillance system established in federally supported specialized bleeding disorders clinics were used in a B19V seroprevalence study. RESULTS: A total of 1643 specimens from 1043 participants age 2 to 7 years born after B19V NAT screening was implemented were tested. Age-specific prevalence rates were generally higher for subjects exposed to either plasma-derived products alone or in combination with other products compared to subjects with no exposure to antihemophilic products. Overall, compared to participants unexposed to blood or blood products, those exposed to plasma-derived products alone were 1.7 times more likely to have antibodies to B19V (p = 0.002). CONCLUSION: These results are consistent with continued B19V transmission through plasma-derived factor concentrates. Effective viral inactivation and detection processes are needed to protect users of these products from infection with B19V or other new or emerging viruses.

AB - BACKGROUND: Parvovirus B19 (B19V) is a small, nonenveloped virus that typically causes a benign flu-like illness that occurs most frequently in childhood. The virus is resistant to current viral inactivation steps used in the manufacture of antihemophilic factor concentrates and B19V transmission through these products has been documented. Since 2000, B19V nucleic acid test (NAT) screening of plasma pools has been implemented to further decrease the viral burden in these products, but no study has examined populations using these products to assess the impact of the screening on B19V transmission. STUDY DESIGN AND METHODS: Blood specimens obtained from participants of a surveillance system established in federally supported specialized bleeding disorders clinics were used in a B19V seroprevalence study. RESULTS: A total of 1643 specimens from 1043 participants age 2 to 7 years born after B19V NAT screening was implemented were tested. Age-specific prevalence rates were generally higher for subjects exposed to either plasma-derived products alone or in combination with other products compared to subjects with no exposure to antihemophilic products. Overall, compared to participants unexposed to blood or blood products, those exposed to plasma-derived products alone were 1.7 times more likely to have antibodies to B19V (p = 0.002). CONCLUSION: These results are consistent with continued B19V transmission through plasma-derived factor concentrates. Effective viral inactivation and detection processes are needed to protect users of these products from infection with B19V or other new or emerging viruses.

UR - http://www.scopus.com/inward/record.url?scp=84877700550&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877700550&partnerID=8YFLogxK

U2 - 10.1111/j.1537-2995.2012.03907.x

DO - 10.1111/j.1537-2995.2012.03907.x

M3 - Article

VL - 53

SP - 1217

EP - 1225

JO - Transfusion

JF - Transfusion

SN - 0041-1132

IS - 6

ER -